Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
myBinderRelated Content
-
Q&A Session on AL Amyloidosis – ASG Webinarhttps://www.youtube.com/watch?v=kvNVKAgl...
-
Doctors Making Progress in Treating AmyloidosisAmyloidosis is a rare condition that use...
-
Carpal Tunnel Syndrome May Triple Your Risk of Developing Stiff Heart SyndromeAccording to a recent study, carpal t...
-
International Society of Amyloidosis (ISA)International Society of Amyloidosis (IS...
-
Stephen J. Kennel, PhDStephen J. Kennel is Professor at The Un...
-
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual MeetingAkcea Therapeutics, Inc. (NASDAQ: AKCA),...
-
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR AmyloidosisThe FDA today granted Alnylam Pharmaceut...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
